Sight Sciences (SGHT)
NASDAQ:SGHT
Top Page
Sight Sciences
(NASDAQ:SGHT)
Select Model
Select Model
Rating:45Neutral
Price Target:
$4.00
▲(13.64% Upside)
Action:ReiteratedDate:03/30/26
The score is held down primarily by weak financial performance (persistent losses, ongoing cash burn, and equity erosion) and a bearish technical setup (price below key moving averages with negative MACD). Offsetting factors include constructive earnings-call momentum with improving profitability trends and FY2026 growth guidance, while valuation is difficult to support due to negative earnings and no dividend yield provided.
Positive Factors
High gross margins
Sustained mid-80s gross margins indicate durable unit economics across devices and consumables. High margins create margin cushion to fund commercial expansion, support reinvestment in market access and R&D, and improve the odds of eventual operating leverage as revenue scales.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow means the business requires external funding or rapid margin and revenue inflection to reach self-sufficiency. Continued cash burn limits strategic optionality and increases reliance on financing during the multi-quarter scaling phase.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained mid-80s gross margins indicate durable unit economics across devices and consumables. High margins create margin cushion to fund commercial expansion, support reinvestment in market access and R&D, and improve the odds of eventual operating leverage as revenue scales.
Read all positive factors
Sight Sciences (SGHT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$190.10M
Dividend YieldN/A
Average Volume (3M)150.61K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue Growth-4.39%
EPS Growth11.70%
CountryUS
Employees216
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.08
Shares Outstanding54,005,985
10 Day Avg. Volume244,568
30 Day Avg. Volume150,613
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)6.47
Price to Sales (P/S)5.35
P/FCF Ratio-13.82
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.08
Enterprise Value/Ebitda-3.79
Forecast
1Y Price Target
$8.83Price Target Upside150.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$84.73M
Sight Sciences Business Overview & Revenue Model
Company Description
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therape...
How the Company Makes Money
Sight Sciences generates revenue primarily from selling ophthalmic devices and related disposable components/consumables used in procedures and treatments performed by eye care professionals. A major revenue stream is the sale and ongoing use of t...
Sight Sciences Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call conveyed constructive operational momentum: revenue growth (+7% Q4), strong 87% gross margins, meaningful operating expense reductions (total OpEx -25%, adjusted OpEx -23%), narrowing net loss, and a major reimbursement milestone (two MACs) enabling a reimbursed TearCare launch. Management provided prudent 2026 guidance ($82M–$88M) that anticipates growth in both Interventional Glaucoma and a scaled Interventional Dry Eye business ($5M–$7M), while also planning targeted commercial and market-access investments. Key risks remain: TearCare is still early-stage and dependent on additional payer wins and commercial scale, cash declined year-over-year and the company remains GAAP-loss-making, and potential future reimbursement code changes (goniotomy) could pressure aspects of the glaucoma market. Overall, positive execution and clear growth initiatives outweigh the remaining operational and reimbursement risks, but realization of the upside depends on successful market access and scaling execution.Positive Updates
Total Revenue Growth
Q4 total revenue was $20.4M, up 7% year-over-year, driven by strength in Interventional Glaucoma and early traction in Interventional Dry Eye.
Negative Updates
Interventional Dry Eye Still Early and Small
Although growing, Interventional Dry Eye revenue remains small at $0.7M for Q4; adoption and scale are constrained by limited commercial infrastructure and payer coverage density (guidance does not assume additional MAC wins).
Read all updates
Q4-2025 Updates
Positive
Negative
Total Revenue Growth
Q4 total revenue was $20.4M, up 7% year-over-year, driven by strength in Interventional Glaucoma and early traction in Interventional Dry Eye.
Read all positive updates
Company Guidance
Management initiated FY2026 revenue guidance of $82–88 million (growth of 6%–14% vs. 2025), comprised of Interventional Glaucoma $77–81M (2%–7% growth) and Interventional Dry Eye $5–7M (vs. $1.6M in 2025); adjusted operating expenses guidance is $93–96M (up 6%–9%) driven by targeted market‑access and commercial investments. They expect Q1 Interventional Glaucoma growth in the low single digits (Q1 is the seasonally lowest quarter) and Interventional Dry Eye of ~ $1M in Q1, with the second half of 2026 anticipated to be stronger than the first, and noted the guidance does not assume additional MAC market‑access wins. Guidance builds off Q4 2025 results: total revenue $20.4M (+7% YoY) with IG $19.7M (+5%) and IDE $0.7M (from $0.3M), gross margin 87% (IG 88%, IDE 68%), Q4 total operating expenses $21.5M (−25%) and adjusted OpEx $18.9M (−23%), net loss $4.2M ($0.08/share) vs. $11.8M ($0.23), ending cash $92M (cash use $0.4M in Q4) and $40M of debt.Sight Sciences Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
52
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 77.36M | 79.87M | 81.06M | 71.33M | 48.96M |
| Gross Profit | 66.67M | 68.28M | 69.17M | 58.97M | 40.35M |
| EBITDA | -36.61M | -45.90M | -49.41M | -80.48M | -57.20M |
| Net Income | -38.43M | -51.51M | -55.55M | -86.24M | -62.96M |
Balance Sheet | |||||
| Total Assets | 115.30M | 142.84M | 166.65M | 213.07M | 280.19M |
| Cash, Cash Equivalents and Short-Term Investments | 91.97M | 120.36M | 138.13M | 185.00M | 260.69M |
| Total Debt | 40.77M | 40.36M | 35.41M | 34.98M | 34.21M |
| Total Liabilities | 51.36M | 55.32M | 46.44M | 53.00M | 48.08M |
| Stockholders Equity | 63.94M | 87.52M | 120.22M | 160.08M | 232.11M |
Cash Flow | |||||
| Free Cash Flow | -29.92M | -22.74M | -47.98M | -76.94M | -53.35M |
| Operating Cash Flow | -29.69M | -22.35M | -47.18M | -75.97M | -52.54M |
| Investing Cash Flow | -224.00K | -385.00K | -791.00K | -970.00K | -813.00K |
| Financing Cash Flow | 1.79M | 4.96M | 1.10M | 1.25M | 252.53M |
Sight Sciences Technical Analysis
Negative
3.52
Price Trends
4.89
Negative
6.29
Negative
5.11
Negative
Market Momentum
-0.36
Negative
35.42
Neutral
34.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGHT, the sentiment is Negative. The current price of 3.52 is below the 20-day moving average (MA) of 3.76, below the 50-day MA of 4.89, and below the 200-day MA of 5.11, indicating a bearish trend. The MACD of -0.36 indicates Negative momentum. The RSI at 35.42 is Neutral, neither overbought nor oversold. The STOCH value of 34.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGHT.
Sight Sciences Risk Analysis
Sight Sciences disclosed 52 risk factors in its most recent earnings report. Sight Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sight Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $116.74M | 14.16 | 4.34% | ― | 3.36% | -21.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $113.64M | -1.98 | 476.59% | ― | 20.59% | 18.61% | |
50 Neutral | $237.07M | -3.47 | -99.33% | ― | 18.44% | 25.42% | |
48 Neutral | $259.94M | -6.74 | 137.18% | ― | 49.52% | 19.34% | |
45 Neutral | $190.10M | -10.76 | -55.72% | ― | -4.39% | 11.70% | |
45 Neutral | $73.30M | -4.06 | 197.15% | ― | 21.02% | -200.88% |
* Healthcare Sector Average
SGHT
Sight Sciences
3.52
1.31
59.28%
FONR
Fonar
18.59
5.59
43.00%
RCEL
Avita Medical
3.71
-4.05
-52.19%
LNSR
LENSAR
6.06
-7.70
-55.96%
TLSI
TriSalus Life Sciences
4.24
-0.91
-17.67%
CVRX
CVRx
9.01
-2.53
-21.92%
Sight Sciences Corporate Events
Business Operations and StrategyFinancial DisclosuresLegal Proceedings
Sight Sciences Wins Key Patent Ruling in Glaucoma Case
Positive
Mar 30, 2026
On March 30, 2026, Sight Sciences announced that the U.S. District Court for the District of Delaware issued a March 27, 2026 order preserving a jury’s verdict that Alcon willfully infringed three of its glaucoma-related patents through sale...
Business Operations and StrategyFinancial Disclosures
Sight Sciences Posts Q4 Growth, Issues 2026 Outlook
Positive
Mar 4, 2026
On March 4, 2026, Sight Sciences reported fourth-quarter 2025 revenue of $20.4 million, up 7% year-on-year, and full-year 2025 revenue of $77.4 million, down 3% versus 2024, as glaucoma sales were flat and dry eye revenue declined for the year. Th...
Business Operations and Strategy
Sight Sciences Extends Menlo Park Headquarters Lease Agreement
Positive
Feb 3, 2026
On January 29, 2026, Sight Sciences, Inc. executed a second amendment to its headquarters lease with Deerfield Campbell, LLC for office space at 4040 Campbell Avenue in Menlo Park, California, extending the existing lease term by 26 months from No...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.